[
  {
    "title": "STAT+: In court, AAP argues Kennedy’s HHS made unlawful changes to vaccine policies",
    "link": "https://www.statnews.com/2026/02/13/rfk-jr-vaccine-lawsuit-pediatricians-challenge-acip-policy-changes/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-13T22:47:48.000Z",
    "summary": "After a day of oral arguments in a packed courtroom, a Boston federal judge did not rule from the bench on a lawsuit from AAP against HHS focused on vaccines."
  },
  {
    "title": "STAT+: FDA rejects rare disease therapy from Disc Medicine, early recipient of commissioner’s voucher",
    "link": "https://www.statnews.com/2026/02/13/disc-medicine-fda-decision/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-13T20:29:19.000Z",
    "summary": "The FDA has rejected a rare disease therapy from Disc Medicine, an early recipient of a commissioner's voucher from the agency."
  },
  {
    "title": "Major shakeup underway at HHS as White House braces for midterms",
    "link": "https://www.statnews.com/2026/02/13/hhs-leadership-changes-rfk-jr-hhs-midterm-elections/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-13T20:13:55.000Z",
    "summary": "Several senior officials are exiting RFK Jr.'s department amid an effort to focus on drug pricing and food issues."
  },
  {
    "title": "Vertex’s CRISPR therapy rebounds in latest earnings",
    "link": "https://www.biopharmadive.com/news/vertex-earnings-casgevy-q4-2025/812243/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-13T18:00:21.000Z",
    "summary": "Sales of Casgevy, a gene-edited treatment developed with CRISPR Therapeutics, more than tripled compared to the third quarter, a performance analysts saw as a bright spot in Vertex's report."
  },
  {
    "title": "Lyell starts first-of-its-kind CAR-T trial; New coalition aims to boost European biotechs",
    "link": "https://www.biopharmadive.com/news/lyell-trial-biotech-europe-biogen-novocure-optum/812059/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-13T16:00:00.000Z",
    "summary": "Lyell’s trial will test its experimental cancer cell therapy directly against marketed counterparts. Elsewhere, Biogen swapped board chairs and venture firms are joining up at a “pivotal time” for…"
  },
  {
    "title": "STAT+: Up and down the ladder: The latest comings and goings",
    "link": "https://www.statnews.com/pharmalot/2026/02/13/pharma-biotech-jobs-lexeo-sanofi-ocugen/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-13T15:39:50.000Z",
    "summary": "From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry."
  },
  {
    "title": "FDA removes box warnings for 6 menopausal therapies",
    "link": "https://www.biopharmadive.com/news/fda-removes-box-warning-six-menopausal-therapies-hrt/812146/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-13T15:16:12.000Z",
    "summary": "The FDA has lifted longstanding and the most severe warnings off of hormone replacement therapies for menopausal women."
  },
  {
    "title": "Ultragenyx cuts jobs as it seeks path to profit in 2027",
    "link": "https://www.biopharmadive.com/news/ultragenyx-cuts-jobs-profitability-earnings-2025-gene-therapy/812204/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-13T15:08:12.000Z",
    "summary": "Another FDA knockback for a gene therapy has investors and analysts redrawing expectations for the rare disease drug developer."
  },
  {
    "title": "STAT+: Pediatricians confront HHS in vaccine showdown",
    "link": "https://www.statnews.com/2026/02/13/biotech-news-pediatricians-confront-hhs-vaccine-showdown/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-13T14:57:20.000Z",
    "summary": "And other biotech news brought to you by The Readout"
  },
  {
    "title": "STAT+: Pharmalittle: We’re reading about Lilly bulking up on weight-loss drugs, scrutiny of a 340B contractor, and more",
    "link": "https://www.statnews.com/pharmalot/2026/02/13/lilly-glp1-obesity-340b-nih-hiv-aids/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-13T14:36:17.000Z",
    "summary": "And other pharma news from the Pharmalot campus today"
  },
  {
    "title": "Moderna shares jump as company affirms growth outlook",
    "link": "https://www.biopharmadive.com/news/moderna-fourth-quarter-2025-financial-earnings/812211/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-13T14:22:39.000Z",
    "summary": "The mRNA specialist reiterated its financial estimates for 2026 amid a challenging U.S. regulatory environment where its influenza vaccine just hit a major setback."
  },
  {
    "title": "HHS shakes ups key advisers",
    "link": "https://www.statnews.com/2026/02/13/health-news-hhs-shakes-up-key-advisors/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-13T12:54:24.000Z",
    "summary": "And other health news from the Morning Rounds newsletter"
  },
  {
    "title": "STAT+: How pediatricians found themselves at war with RFK Jr.",
    "link": "https://www.statnews.com/2026/02/13/american-academy-pediatrics-becomes-maha-vaccine-foil/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-13T09:30:00.000Z",
    "summary": "The AAP has become a leading opponent of MAHA and RFK Jr.'s vaccine agenda."
  },
  {
    "title": "Opinion: America’s disease surveillance system is going dark. Here’s what we can build to replace it",
    "link": "https://www.statnews.com/2026/02/13/cdc-surveillance-dismantled-rebuild-early-warning-systems/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-13T09:30:00.000Z",
    "summary": "America’s disease surveillance system is broken. Here’s how to replace it."
  },
  {
    "title": "Opinion: Pharmacist oversight must be built into prescription kiosks",
    "link": "https://www.statnews.com/2026/02/13/pharmacy-kiosks-automated-medication-dispensing-safety/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-13T09:30:00.000Z",
    "summary": "Pharmacy kiosks can expand access and convenience, but only when paired with pharmacist-led safeguards that ensure safe and coordinated medication use."
  },
  {
    "title": "STAT+: Moderna’s president weighs in on FDA’s decision not to review its flu vaccine",
    "link": "https://www.statnews.com/2026/02/12/moderna-stephen-hoge-interview-flu-vaccine/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-12T23:23:20.000Z",
    "summary": "In an interview, Moderna President Stephen Hoge took questions on an FDA decision on the biotech's mRNA flu vaccine, as well as the impact on the company and others in…"
  },
  {
    "title": "The FDA’s refusal to review Moderna’s mRNA flu vaccine",
    "link": "https://www.statnews.com/2026/02/12/readout-loud-podcast-moderna-fda-vinay-prasad-vaccine/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-12T23:13:15.000Z",
    "summary": "This week on \"The Readout LOUD,\" everything you need to know about the FDA's controversial decision to block the review of Moderna’s mRNA flu shot."
  },
  {
    "title": "Earnings roundup: Neurocrine slumps, Alnylam battles skeptics and Ascendis eyes a competitor",
    "link": "https://www.biopharmadive.com/news/alnylam-neurocrine-ascendis-biotech-earnings-4q-2025/812137/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-12T22:23:00.000Z",
    "summary": "Neurocrine and Alnylam each face investor questions about the growth potential of key franchises. Ascendis, meanwhile, saw an upbeat sales report overshadowed by the progress of an emerging rival."
  },
  {
    "title": "STAT+: Trump administration is urged to use a federal law to authorize generic versions of GLP-1 drugs",
    "link": "https://www.statnews.com/pharmalot/2026/02/12/patents-obesity-novo-lilly-generics-wegovy-zepbound/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-12T22:00:46.000Z",
    "summary": "Public Citizen contends that Novo Nordisk and Eli Lilly's obesity drugs are straining budgets so much that generics should be authorized."
  },
  {
    "title": "STAT+: FDA’s rejection of Moderna threatens to stifle broader vaccine industry",
    "link": "https://www.statnews.com/2026/02/12/fda-moderna-rejection-upends-vaccine-industry/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-12T17:49:04.000Z",
    "summary": "Experts say the FDA \"moved the goalposts\" on Moderna, creating \"a destructive precedent that will undermine the future of vaccine development\" in the U.S."
  },
  {
    "title": "Seres to lay off staff, pause top program in latest reboot",
    "link": "https://www.biopharmadive.com/news/seres-layoffs-restructuring-microbiome-immune-disease/812079/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-12T17:00:00.000Z",
    "summary": "The microbiome specialist, which for years has struggled to stay afloat, is cutting its staff by 30% and focusing resources on earlier, immunology-focused research."
  },
  {
    "title": "STAT+: The messaging war over Medicaid cuts",
    "link": "https://www.statnews.com/2026/02/12/messaging-war-over-medicaid-cuts-moderna-rejection-dc-diagnosis-newsletter/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-12T16:55:50.000Z",
    "summary": "This is the web edition of STAT's D.C. Diagnosis newsletter."
  },
  {
    "title": "Lowering drug costs is on Republicans’ minds. Democrats say GOP policies don’t help.",
    "link": "https://www.biopharmadive.com/news/drug-costs-supply-chain-energy-commerce-pharmacy-benefit-managers-gop-policies/812096/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-12T16:55:00.000Z",
    "summary": "At a House subcommittee hearing on Wednesday, lawmakers on both sides of the aisle decried the nation’s high drug costs, but Democrats argued Medicaid cuts and lapsed Affordable Care Act subsidies…"
  },
  {
    "title": "FDA Approves Labeling Changes to Menopausal Hormone Therapy Products",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products",
    "source": "FDA Press Releases",
    "category": "regulatory",
    "date": "2026-02-12T16:17:42.000Z",
    "summary": "The U.S. Food and Drug Administration has approved drug labeling changes to six menopausal hormone therapy products, also known as hormone replacement therapy (HRT), to clarify risk considerations…"
  },
  {
    "title": "STAT+: NIH redefines ‘clinical trials,’ dividing researchers",
    "link": "https://www.statnews.com/pharmalot/2026/02/12/nih-clinical-trial-definition-research-transparency/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-12T15:59:47.000Z",
    "summary": "In a long-debated move, the NIH will no longer characterize basic experimental studies involving humans as clinical trials."
  },
  {
    "title": "Sanofi, looking for more ‘rigor,’ swaps CEO Hudson for ex-Merck KGaA chief Garijo",
    "link": "https://www.biopharmadive.com/news/sanofi-ceo-paul-hudson-belen-garijo/812061/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-12T15:55:00.000Z",
    "summary": "The move drew skepticism from investors despite multiple recent research setbacks that have left questions about Sanofi’s ability to confront Dupixent’s looming patent expiration."
  },
  {
    "title": "STAT+: A change at the top of Sanofi",
    "link": "https://www.statnews.com/2026/02/12/biotech-news-sanofi-ceo-paul-hudson-out/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-12T14:31:59.000Z",
    "summary": "And other biotech news brought to you by The Readout newsletter"
  },
  {
    "title": "STAT+: Pharmalittle: We’re reading about Sanofi replacing its CEO, MFN drug pricing opposed by conservatives, and more",
    "link": "https://www.statnews.com/pharmalot/2026/02/12/trump-sanofi-abbvie-novo-lilly-gsk-teva-merck-bristol/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-12T14:25:06.000Z",
    "summary": "And other pharma news from the Pharmalot campus via the Pharmalittle newsletter"
  },
  {
    "title": "STAT+: Researchers take another look at Apple’s hypertension feature",
    "link": "https://www.statnews.com/2026/02/12/talkiatry-big-health-funding-bonanza-apple-health-tech/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-12T13:42:51.000Z",
    "summary": "In this edition of STAT Health Tech: Fundraises by Talkiatry, Big Health, and the accuracy of Apple Watch hypertension feature."
  },
  {
    "title": "FDA Approves First-of-Its-Kind Device to Treat Pancreatic Cancer",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-device-treat-pancreatic-cancer",
    "source": "FDA Press Releases",
    "category": "regulatory",
    "date": "2026-02-12T13:33:59.000Z",
    "summary": "The U.S. Food and Drug Administration has approved a first-of-its-kind device for the treatment of adult patients with locally advanced pancreatic cancer."
  },
  {
    "title": "STAT+: Big Health raises funding as investors see glimmer of hope for digital therapeutics",
    "link": "https://www.statnews.com/2026/02/12/big-health-fundraise-investors-bet-dtx-promise/?utm_campaign=rss",
    "source": "STAT News",
    "category": "industry",
    "date": "2026-02-12T13:00:00.000Z",
    "summary": "Big Health raises $24 million as investors bet that digital therapeutics' time has finally arrived."
  },
  {
    "title": "BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis",
    "link": "https://www.biopharmadive.com/news/bridgebio-dwarfism-drug-data-infigratinib-achondroplasia-biomarin-ascendis/812034/",
    "source": "BioPharma Dive",
    "category": "industry",
    "date": "2026-02-12T12:30:00.000Z",
    "summary": "The latest in a string of clinical wins, the late-stage data gives the company strong footing to compete with BioMarin's top seller."
  },
  {
    "title": "FDA Launches Assessment of BHA, a Common Food Chemical Preservative",
    "link": "http://www.fda.gov/news-events/press-announcements/fda-launches-assessment-bha-common-food-chemical-preservative",
    "source": "FDA Press Releases",
    "category": "regulatory",
    "date": "2026-02-10T14:13:25.000Z",
    "summary": "The U.S. Food and Drug Administration today launched a comprehensive re-assessment of butylated hydroxyanisole (BHA), a chemical preservative used in food."
  }
]
